Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;66(1):85-109.
doi: 10.2165/00003495-200666010-00005.

Pioglitazone: a review of its use in type 2 diabetes mellitus

John Waugh  1 , Gillian M Keating, Greg L Plosker, Stephanie Easthope, Dean M Robinson
Affiliations
Review

Pioglitazone: a review of its use in type 2 diabetes mellitus

John Waugh et al. Drugs. 2006.

Erratum in

  • Drugs. 2006;66(3):340-1

Abstract

Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone is generally well tolerated, weight gain and oedema are the most common emergent adverse events, and there are no known drug interactions between pioglitazone and other drugs. In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles. Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Diabetes. 2000 Apr;49(4):539-47 - PubMed
    1. Ann Intern Med. 2002 Mar 19;136(6):449-52 - PubMed
    1. Coron Artery Dis. 2001 Aug;12(5):413-23 - PubMed
    1. Am J Gastroenterol. 2002 Feb;97(2):502-3 - PubMed
    1. J Clin Endocrinol Metab. 2001 Jul;86(7):3452-6 - PubMed

MeSH terms

LinkOut - more resources

  NODES
admin 2
INTERN 3
twitter 2